Valuation: BLS Pharmaceuticals Limited

Market Cap 213M 149M 130M 121M 111M 209M 14.21B 1.43B 559M 7.09B 560M 548M 23.38B P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 207M 145M 126M 117M 108M 203M 13.8B 1.39B 543M 6.88B 544M 532M 22.7B EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
45.12%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 131M
-0.36%+0.14%-0.95%+14.33% 48.53B
-2.40%-2.45%+393.44%+475.29% 39.87B
-1.11%+8.86%+27.01%+7.31% 38.68B
-1.38%-4.66%+2.11%+50.96% 35.13B
-2.41%+2.59%+11.68%+41.16% 29.79B
-0.29%-2.65%+32.67%+122.34% 16.11B
+0.10%-4.11% - - 16.08B
-0.62%+1.23%+1.80%+15.05% 13.61B
-3.19%-7.17%-4.93%-37.59% 12.62B
Average -1.21%+0.86%+57.85%+86.11% 27.82B
Weighted average by Cap. -1.26%+1.82%+75.08%+105.17%

Financials

2024 2025
Net sales 9.64M 6.75M 5.86M 5.48M 5.03M 9.48M 643M 64.56M 25.28M 321M 25.35M 24.78M 1.06B 29.28M 20.49M 17.81M 16.63M 15.26M 28.78M 1.95B 196M 76.78M 974M 76.96M 75.26M 3.21B
Net income -13.33M -9.32M -8.1M -7.57M -6.95M -13.1M -889M -89.21M -34.94M -443M -35.03M -34.25M -1.46B 4.9M 3.43M 2.98M 2.78M 2.55M 4.82M 327M 32.81M 12.85M 163M 12.88M 12.6M 538M
Net Debt -318K -222K -193K -180K -166K -312K -21.18M -2.13M -833K -10.56M -835K -816K -34.84M -6.13M -4.29M -3.73M -3.48M -3.2M -6.03M -409M -41.07M -16.08M -204M -16.12M -15.77M -673M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-

Annual profits - Rate of surprise